聚桂醇联合平阳霉素治疗120例静脉畸形疗效观察

上海口腔医学 ›› 2016, Vol. 25 ›› Issue (5): 588-592.

聚桂醇联合平阳霉素治疗120例静脉畸形疗效观察

刘莉¹, 刘冬晓², 赵吉宏², 蔡育², 钟皓研²

1.三峡大学第三临床医学院·葛洲坝集团中心医院口腔科,湖北宜昌 443002；
2.武汉大学口腔医学院口腔颌面外科,湖北武汉 430079

收稿日期:2015-10-19 修回日期:2015-12-23 出版日期:2016-10-25 发布日期:2016-11-10
通讯作者: 赵吉宏,E-mail：jhzhao988@163.com
作者简介:刘莉（1968-）,女,学士,主任医师, E-mail：1695194772@qq.com

Clinical efficacy of lauromacrogol combined with pingyangmycin in the treatment of venous malformation: clinical analysis of 120 consecutive cases

LIU Li¹, LIU Dong-xiao², ZHAO Ji-hong², CAI Yu², ZHONG Hao-yan²

1. Department of Stomatology, Gezhouba Central Hospital, Third Clinical College, Three Gorge University. Yichang 443002;
2. Department of Oral and Maxillofacial Surgery, School of Stomatology, Wuhan University. Wuhan 430079, Hubei Province, China

Received:2015-10-19 Revised:2015-12-23 Online:2016-10-25 Published:2016-11-10

摘要/Abstract

摘要： 目的通过与平阳霉素局部注射治疗静脉畸形对比,观察聚桂醇联合平阳霉素局部注射治疗静脉畸形的临床效果。方法选取口腔颌面-颈部静脉畸形患者120例,病变直径4.0~6.0 cm,随机分为实验组（60例）和对照组（60例）,实验组采用聚桂醇联合平阳霉素局部注射治疗,两者间隔2周交替使用;对照组仅使用平阳霉素进行局部注射治疗,间隔2周注射1次,观察治疗后病变缩小程度、局部颜色、质地、体位试验变化及不良反应。采用SPSS 11.5软件包对数据进行统计学分析。结果根据国际疗效评价标准,第2、3、4、5次治疗后,实验组的治疗效果显著优于对照组（P<0.05）;第1、6次治疗后实验组与对照组的治疗效果未见显著差异（P>0.05）;实验组治疗有效的平均次数显著少于对照组（P<0.05）。结论聚桂醇联合平阳霉素治疗静脉畸形与单纯使用平阳霉素相比,可提高疗效、缩短疗程,无明显不良反应。

关键词: 聚桂醇, 平阳霉素, 静脉畸形

Abstract: PURPOSE: To compare the clinical efficacy of pingyangmycin and lauromacrogol combined with pingyangmycin in the treatment of venous malformations (VMs). METHODS: One hundred and twenty patients with VM were randomly divided into lauromacrogol combined with pingyangmycin injection group (experimental group) and pingyangmycin injection group (control group). The appropriate interval between different injection sessions was 2 weeks. After different sessions, the changes of lesions (including size, color, texture) as well as the results of posture test and adverse effects were analyzed by using SPSS11.5 software package. RESULTS: According to the international evaluation criteria for VM, the efficacy of the experimental group was significantly better than the control group after 2~5 sessions (P<0.05). However, after 1 and 6 sessions, there was no significant difference in the efficacy between the experimental group and the control group (P>0.05). In addition, the average sessions required in the experimental group were significantly less than those in the control group (P<0.05). CONCLUSIONS: Compared to the single use of pingyangmycin, lauromacrogol combined with pingyangmycin is more effective for the treatment of VM, with fewer sessions required and no adverse effects.

Key words: Lauromacrogol, Pingyangmycin, Venous malformation

中图分类号:

R782

刘莉, 刘冬晓, 赵吉宏, 蔡育, 钟皓研. 聚桂醇联合平阳霉素治疗120例静脉畸形疗效观察[J]. 上海口腔医学, 2016, 25(5): 588-592.

LIU Li, LIU Dong-xiao, ZHAO Ji-hong, CAI Yu, ZHONG Hao-yan. Clinical efficacy of lauromacrogol combined with pingyangmycin in the treatment of venous malformation: clinical analysis of 120 consecutive cases[J]. Shanghai Journal of Stomatology, 2016, 25(5): 588-592.

参考文献

[1] Redondo P. Vascular malformations: concept, classification, pathogenesis and clinical features [J]. Actas Dermosifiliogr, 2007, 98(3): 141-158.
[2] Buckmiller LM, Richter GT, Suen JY. Diagnosis and management of hemangiomas and vascular malformations of the head and neck [J]. Oral Dis, 2010, 16(5): 405-418.
[3] Blaise S, Charavin-Cocuzza M, Riom H, et al. Treatment of low flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review[J]. Eur J Vasc Endovasc Surg, 2011, 41(3): 412-417.
[4] 中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组. 口腔颌面-头颈部静脉畸形诊治指南 [J]. 中国口腔颌面外科杂志, 2011, 9(6): 510-517.
[5] Bai N, Chen YZ, Fu YJ, et al. A clinical study of pingyangmycin sclerotherapy for venous malformation: an evaluation of 281 consecutive patients[J]. J Clin Pharm Ther, 2014, 39(5): 521-526.
[6] Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients [J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[7] Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities [J]. Arch Dermatol, 2004, 140(8): 971-976.
[8] Meijer-Jorna LB, Breugem CC, de Boer OJ, et al. Presence of a distinct neural component in congenital vascular malformations relates to the histological type and location of the lesion [J]. Hum Pathol, 2009, 40(10): 1467-1473.
[9] Lee BB, Do YS, Byun HS, et al. Advanced management of venous malformation with ethanol sclerotherapy: mid-term results [J]. J Vasc Surg, 2003, 37(3): 533-538.
[10] 张志愿, 赵怡芳. 头颈部血管瘤与脉管畸形 [M]. 上海: 世界图书出版社, 2007: 5.
[11] Zhao JH, Zhang WF, Zhao YF. Sclerotherapy of oral and facial venous malformations with use of pingyangmycin and/or sodium morrhuate [J]. Int J Oral Maxillofac Surg, 2004, 33(5): 463-466.
[12] 吴洪斌, 陆国椿. 平阳霉素的不良反应 [J]. 中国临床药学杂志, 2001, 10(1): 53-55.
[13] Weiss RA, Feied CF, Weiss MA. Vein diagnosis and treatment: a comprehensive approach[M]. New York: McGraw Hill, 2001: 126.
[14] Goldman MP, Bergan JJ, Guex JJ. Sclerotherapy: treatment of varicose and telangiectactic leg veins[M]. 4th Ed. Philadelphia: Mosby Elsevier, 2007.
[15] Bergan J, Cheng VL（李龙译）. 泡沫硬化疗法教程[M]. 北京:人民军医出版社, 2009: 165-169.
[16] 刘启宁. 泡沫硬化治疗下肢静脉曲张研究进展 [J]. 实用医院临床杂志, 2013, 10(3): 165-167.
[17] Zhao JH, Zhao YF, Chen XM, et al. Histological investigation of veins and venous malformations after injection of sclerosing agents [J]. Asian J Oral Maxillofac Surg, 2002, 14(4): 226-231.